SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Gibson Julie) "

Sökning: WFRF:(Gibson Julie)

  • Resultat 1-10 av 12
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Akinsete, Ebun, et al. (författare)
  • Sustainable WEF Nexus Management: A Conceptual Framework to Integrate Models of Social, Economic, Policy, and Institutional Developments
  • 2022
  • Ingår i: Frontiers in Water. - : FRONTIERS MEDIA SA. - 2624-9375. ; 4
  • Forskningsöversikt (refereegranskat)abstract
    • Rapid population growth along with increased rates of economic growth around the globe are placing valuable natural resources, water in particular, under unprecedented stress; this in turn drives the pursuit of innovative tools to support integrated Water-Energy-Food (WEF) nexus management. This paper presents a framework for the integrated management of the WEF nexus, which brings together four separate models that address the less well-examined socio-anthropological aspects of the nexus. The proposed framework provides insight into the human element as part of the wider ecosystem in terms of socio-cultural and economic activities, the laws and policies that govern these activities, as well as their potential socio-economic impacts and consequences. This paper outlines each individual model, before going on to present a conceptual framework for the integration of the various models for the purpose of supporting more robust decision-making. The framework, which is grounded in systems thinking, adopts the principles of sustainable development as structural foci in order to position the various models in relation to one another; harmonizing their inputs as well as outputs.
  •  
3.
  •  
4.
  • Dai, Qile, et al. (författare)
  • OTTERS: a powerful TWAS framework leveraging summary-level reference data
  • 2023
  • Ingår i: Nature Communications. - : Springer Nature. - 2041-1723. ; 14:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Most existing TWAS tools require individual-level eQTL reference data and thus are not applicable to summary-level reference eQTL datasets. The development of TWAS methods that can harness summary-level reference data is valuable to enable TWAS in broader settings and enhance power due to increased reference sample size. Thus, we develop a TWAS framework called OTTERS (Omnibus Transcriptome Test using Expression Reference Summary data) that adapts multiple polygenic risk score (PRS) methods to estimate eQTL weights from summary-level eQTL reference data and conducts an omnibus TWAS. We show that OTTERS is a practical and powerful TWAS tool by both simulations and application studies.
  •  
5.
  • Gloriam, David E., et al. (författare)
  • A Community Standard Format for the Representation of Protein Affinity Reagents
  • 2010
  • Ingår i: Molecular & Cellular Proteomics. - 1535-9476 .- 1535-9484. ; 9:1, s. 1-10
  • Tidskriftsartikel (refereegranskat)abstract
    • Protein affinity reagents (PARs), most commonly antibodies, are essential reagents for protein characterization in basic research, biotechnology, and diagnostics as well as the fastest growing class of therapeutics. Large numbers of PARs are available commercially; however, their quality is often uncertain. In addition, currently available PARs cover only a fraction of the human proteome, and their cost is prohibitive for proteome scale applications. This situation has triggered several initiatives involving large scale generation and validation of antibodies, for example the Swedish Human Protein Atlas and the German Antibody Factory. Antibodies targeting specific subproteomes are being pursued by members of Human Proteome Organisation (plasma and liver proteome projects) and the United States National Cancer Institute (cancer-associated antigens). ProteomeBinders, a European consortium, aims to set up a resource of consistently quality-controlled protein-binding reagents for the whole human proteome. An ultimate PAR database resource would allow consumers to visit one online warehouse and find all available affinity reagents from different providers together with documentation that facilitates easy comparison of their cost and quality. However, in contrast to, for example, nucleotide databases among which data are synchronized between the major data providers, current PAR producers, quality control centers, and commercial companies all use incompatible formats, hindering data exchange. Here we propose Proteomics Standards Initiative (PSI)-PAR as a global community standard format for the representation and exchange of protein affinity reagent data. The PSI-PAR format is maintained by the Human Proteome Organisation PSI and was developed within the context of ProteomeBinders by building on a mature proteomics standard format, PSI-molecular interaction, which is a widely accepted and established community standard for molecular interaction data. Further information and documentation are available on the PSI-PAR web site. Molecular & Cellular Proteomics 9: 1-10, 2010.
  •  
6.
  • Kattge, Jens, et al. (författare)
  • TRY plant trait database - enhanced coverage and open access
  • 2020
  • Ingår i: Global Change Biology. - : Wiley-Blackwell. - 1354-1013 .- 1365-2486. ; 26:1, s. 119-188
  • Tidskriftsartikel (refereegranskat)abstract
    • Plant traits-the morphological, anatomical, physiological, biochemical and phenological characteristics of plants-determine how plants respond to environmental factors, affect other trophic levels, and influence ecosystem properties and their benefits and detriments to people. Plant trait data thus represent the basis for a vast area of research spanning from evolutionary biology, community and functional ecology, to biodiversity conservation, ecosystem and landscape management, restoration, biogeography and earth system modelling. Since its foundation in 2007, the TRY database of plant traits has grown continuously. It now provides unprecedented data coverage under an open access data policy and is the main plant trait database used by the research community worldwide. Increasingly, the TRY database also supports new frontiers of trait-based plant research, including the identification of data gaps and the subsequent mobilization or measurement of new data. To support this development, in this article we evaluate the extent of the trait data compiled in TRY and analyse emerging patterns of data coverage and representativeness. Best species coverage is achieved for categorical traits-almost complete coverage for 'plant growth form'. However, most traits relevant for ecology and vegetation modelling are characterized by continuous intraspecific variation and trait-environmental relationships. These traits have to be measured on individual plants in their respective environment. Despite unprecedented data coverage, we observe a humbling lack of completeness and representativeness of these continuous traits in many aspects. We, therefore, conclude that reducing data gaps and biases in the TRY database remains a key challenge and requires a coordinated approach to data mobilization and trait measurements. This can only be achieved in collaboration with other initiatives.
  •  
7.
  • Lazar, Tamas, et al. (författare)
  • PED in 2021 : A major update of the protein ensemble database for intrinsically disordered proteins
  • 2021
  • Ingår i: Nucleic Acids Research. - : Oxford University Press (OUP). - 0305-1048 .- 1362-4962. ; 49:D1, s. 404-411
  • Tidskriftsartikel (refereegranskat)abstract
    • The Protein Ensemble Database (PED) (https://proteinensemble.org), which holds structural ensembles of intrinsically disordered proteins (IDPs), has been significantly updated and upgraded since its last release in 2016. The new version, PED 4.0, has been completely redesigned and reimplemented with cutting-edge technology and now holds about six times more data (162 versus 24 entries and 242 versus 60 structural ensembles) and a broader representation of state of the art ensemble generation methods than the previous version. The database has a completely renewed graphical interface with an interactive feature viewer for region-based annotations, and provides a series of descriptors of the qualitative and quantitative properties of the ensembles. High quality of the data is guaranteed by a new submission process, which combines both automatic and manual evaluation steps. A team of biocurators integrate structured metadata describing the ensemble generation methodology, experimental constraints and conditions. A new search engine allows the user to build advanced queries and search all entry fields including cross-references to IDP-related resources such as DisProt, MobiDB, BMRB and SASBDB. We expect that the renewed PED will be useful for researchers interested in the atomic-level understanding of IDP function, and promote the rational, structure-based design of IDP-targeting drugs.
  •  
8.
  • Loeffen, Erik A. H., et al. (författare)
  • Reducing pain in children with cancer : Methodology for the development of a clinical practice guideline
  • 2019
  • Ingår i: Pediatric Blood & Cancer. - : Wiley. - 1545-5009 .- 1545-5017. ; 66:6
  • Tidskriftsartikel (refereegranskat)abstract
    • Although pain is one of the most prevalent and bothersome symptoms children with cancer experience, evidence-based guidance regarding assessment and management is lacking. With 44 international, multidisciplinary healthcare professionals and nine patient representatives, we aimed to develop a clinical practice guideline (following GRADE methodology), addressing assessment and pharmacological, psychological, and physical management of tumor-, treatment-, and procedure-related pain in children with cancer. In this paper, we present our thorough methodology for this development, including the challenges we faced and how we approached these. This lays the foundation for our clinical practice guideline, for which there is a high clinical demand.
  •  
9.
  • Margaryan, Ashot, et al. (författare)
  • Population genomics of the Viking world
  • 2020
  • Ingår i: Nature. - : Springer Science and Business Media LLC. - 1476-4687 .- 0028-0836. ; 585:7825, s. 390-396
  • Tidskriftsartikel (refereegranskat)abstract
    • The maritime expansion of Scandinavian populations during the Viking Age (about ad750–1050) was a far-flung transformation in world history1,2. Here we sequenced the genomes of 442humans from archaeological sites across Europe and Greenland (to a median depth of about 1×) to understand the global influence of this expansion. We find the Viking period involved gene flow into Scandinavia from the south and east. We observe genetic structure within Scandinavia, with diversity hotspots in the south and restricted gene flow within Scandinavia. We find evidence for a major influx of Danish ancestry into England; a Swedish influx into the Baltic; and Norwegian influx into Ireland, Iceland and Greenland. Additionally, we see substantial ancestry from elsewhere in Europe entering Scandinavia during the Viking Age. Our ancient DNA analysis also revealed that a Viking expedition included close family members. By comparing with modern populations, we find that pigmentation-associated loci have undergone strong population differentiation during the past millennium, and trace positively selected loci—including the lactase-persistence allele of LCT and alleles of ANKA that are associated with the immune response—in detail. We conclude that the Viking diaspora was characterized by substantial transregional engagement: distinct populations influenced the genomic makeup of different regions of Europe, and Scandinavia experienced increased contact with the rest of the continent.
  •  
10.
  • Parkinson, Lynne, et al. (författare)
  • An observational study of the discrediting of COX-2 NSAIDs in Australia : Vioxx or class effect?
  • 2011
  • Ingår i: BMC Public Health. - : Springer. - 1471-2458. ; 11, s. 892-
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: When a medicine such as rofecoxib (Vioxx) is withdrawn, or a whole class of medicines discredited such as the selective COX-2 inhibitors (COX-2s), follow-up of impacts at consumer level can be difficult and costly. The Australian Longitudinal Study on Women's Health provides a rare opportunity to examine individual consumer medicine use following a major discrediting event, the withdrawal of rofecoxib and issuing of safety warnings on the COX-2 class of medicines. The overall objective of this paper was to examine the impact of this discrediting event on dispensing of the COX-2 class of medicines, by describing medicine switching behaviours of older Australian women using rofecoxib in September 2004; the uptake of other COX-2s; and the characteristics of women who continued using a COX-2.METHODS: Participants were concessional beneficiary status women from the Older cohort (born 1921-26) of the Australian Longitudinal Study on Women's Health who consented to linkage to Pharmaceutical Benefits Scheme data, with at least one rofecoxib prescription dispensed in the 12 months before rofecoxib withdrawal. A prescription was defined as one dispensing occasion. Women were grouped by rofecoxib pattern of use: continuous (nine or more prescriptions dispensed in the 12 months prior to rofecoxib withdrawal) or non-continuous (eight or less prescriptions dispensed in the 12 months prior to rofecoxib withdrawal) users. Incidence rate per 100,000 person days and incidence risk ratio described uptake of alternate medicines, following rofecoxib withdrawal. Kaplan-Meier curves described differences in uptake patterns by medicine and pattern of rofecoxib use. Patterns of use of COX-2s in the next 100 days after first COX-2 uptake were described.RESULTS: Medicine switches and pattern of medicines uptake differed significantly depending upon whether a woman was a continuous or non-continuous rofecoxib user prior to rofecoxib discrediting. Continuous rofecoxib users overwhelmingly switched to another COX-2 and remained continuing COX-2 users for at least 100 days post-switch.CONCLUSIONS: The typical switching behaviour of this group of women suggests that the issues leading to the discrediting of rofecoxib were not seen as a COX-2 class effect by prescribers to this high use group of consumers.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 12
Typ av publikation
tidskriftsartikel (11)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (11)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Borrebaeck, Carl (2)
Zhang, Yan (1)
Svergun, Dmitri (1)
Korhonen, Laura (1)
Lindholm, Dan (1)
Diaz, Sandra (1)
visa fler...
Galbany, Lluís (1)
Vertessy, Beata G. (1)
Ostonen, Ivika (1)
Tedersoo, Leho (1)
Bond-Lamberty, Ben (1)
Wang, Mei (1)
Uhlén, Mathias (1)
Wang, Xin (1)
Liu, Yang (1)
Kumar, Rakesh (1)
Wang, Dong (1)
Perola, Markus (1)
Gustafsson, Jörgen (1)
Li, Cheng (1)
Li, Ke (1)
Liu, Ke (1)
Zhang, Yang (1)
Prieto, Carlos Allen ... (1)
Holtzman, Jon A. (1)
Anders, Friedrich (1)
Anderson, Scott F. (1)
Andrews, Brett H. (1)
Anguiano, Borja (1)
Aragon-Salamanca, Al ... (1)
Argudo-Fernandez, Ma ... (1)
Ata, Metin (1)
Avila-Reese, Vladimi ... (1)
Badenes, Carles (1)
Beers, Timothy C. (1)
Belfiore, Francesco (1)
Bender, Chad F. (1)
Bernardi, Mariangela (1)
Bershady, Matthew A. (1)
Beutler, Florian (1)
Bird, Jonathan C. (1)
Bizyaev, Dmitry (1)
Blanc, Guillermo A. (1)
Blanton, Michael R. (1)
Bolton, Adam S. (1)
Boquien, Mederic (1)
Borissova, Jura (1)
Bovy, Jo (1)
Brownstein, Joel R. (1)
Bundy, Kevin (1)
visa färre...
Lärosäte
Lunds universitet (6)
Uppsala universitet (3)
Stockholms universitet (3)
Sveriges Lantbruksuniversitet (3)
Göteborgs universitet (2)
Umeå universitet (2)
visa fler...
Kungliga Tekniska Högskolan (2)
Linköpings universitet (2)
Luleå tekniska universitet (1)
Malmö universitet (1)
Karlstads universitet (1)
Karolinska Institutet (1)
visa färre...
Språk
Engelska (12)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (6)
Medicin och hälsovetenskap (6)
Samhällsvetenskap (2)
Teknik (1)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy